Abbott presented 11 new studies at ASCO 2026 demonstrating advances in cancer diagnostics that improve early detection, treatment guidance, and patient outcomes. Key data include enhanced sensitivity in early triple-negative breast cancer and low psychological burden from multi-cancer early detection tests. These innovations support more precise, personalized cancer care without increasing patient stress, marking a shift toward integrated diagnostics from risk assessment to remission monitoring. Abbott's portfolio spans tests like Cancerguard MCED, Oncodetect MRD, and Oncotype DX Breast Recurrence Score, highlighting their role in transforming cancer management.
Abbott has received CE Mark approval for Libre Duo, the world's first sensor that continuously monitors both glucose and ketone levels for people with diabetes. This device helps manage daily glucose and detects rising ketones that can lead to danger...
The American Cancer Society (ACS) updated its colorectal cancer screening guidelines, reaffirming Cologuard and Cologuard Plus as preferred noninvasive screening tests for adults aged 45 and older at average risk. These stool-based tests, used every ...
